Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients

Abstract

Insulin/IGF-I hybrid receptors composed of an insulin receptor (IR) α β-hemireceptor and a type 1 IGF receptor (IGF-IR) α β-hemireceptor are formed in tissues expressing both molecules. To date there is a limited information about the proportion of hybrids in tissues of normal or diabetic subjects. In this study, we determined the abundance of hybrids in fat from control and NIDDM subjects by using a microwell-based immunoassay. Microwells coated with MA-20 anti-IR or α-IGF-IR-PA anti-IGF-IR antibody were incubated with tissue extracts. Immunoadsorbed receptors were incubated with 125I-insulin or 125I-IGF-I in the presence or absence of unlabeled ligands, and hybrids were quantitated as the fraction of 125I-IGF-I binding immunoadsorbed with MA-20. Abundance of hybrids was increased in NIDDM patients as compared with controls (B/T=1.29±0.18 and 0.52±0.06%; P<0.008, respectively), and it was inversely correlated with both IR number ( r=−0.65; P<0.002), and in vivo insulin sensitivity measured by insulin tolerance test ( r=−0.75; P<0.005), whereas it was positively correlated with insulinemia ( r=0.63; P<0.003). Insulin binding affinity was lower in NIDDM subjects than in controls (ED 50=1.87±0.32 and 0.54±0.20 nmol/l; P<0.009, respectively), and was correlated with the percentage of hybrids. Maximal IGF-I binding was significantly greater in NIDDM patients than controls and was positively correlated with the percentage of hybrids whereas IGF-I binding affinity did not differ between the two groups. Results show that expression of hybrids is increased in fat of NIDDM patients compared to control subjects and is correlated with in vivo insulin sensitivity thus raising the possibility that alterations in expression of hybrids which bind IGF-I with higher affinity than insulin may contribute, at least in part, to insulin resistance.